Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,697 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Desire for information and involvement in treatment decisions: lung cancer patients' preferences and their physicians' perceptions: results from Okayama Lung Cancer Study Group Trial 0705.
Hotta K, Kiura K, Takigawa N, Yoshioka H, Hayashi H, Fukuyama H, Nishiyama A, Yokoyama T, Kuyama S, Umemura S, Kato Y, Nogami N, Segawa Y, Yasugi M, Tabata M, Tanimoto M. Hotta K, et al. Among authors: kato y. J Thorac Oncol. 2010 Oct;5(10):1668-72. doi: 10.1097/JTO.0b013e3181f1c8cb. J Thorac Oncol. 2010. PMID: 20871267 Free article.
Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience.
Kato Y, Hotta K, Takigawa N, Nogami N, Kozuki T, Sato A, Ichihara E, Kudo K, Oze I, Tabata M, Shinkai T, Tanimoto M, Kiura K. Kato Y, et al. Cancer Chemother Pharmacol. 2014 May;73(5):943-50. doi: 10.1007/s00280-014-2425-9. Epub 2014 Mar 16. Cancer Chemother Pharmacol. 2014. PMID: 24633759
A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.
Aoe K, Takigawa N, Hotta K, Maeda T, Kishino D, Nogami N, Tabata M, Harita S, Okada T, Kubo T, Hosokawa S, Fujiwara K, Gemba K, Yasugi M, Kozuki T, Kato Y, Katsui K, Kanazawa S, Ueoka H, Tanimoto M, Kiura K. Aoe K, et al. Among authors: kato y. Eur J Cancer. 2014 Nov;50(16):2783-90. doi: 10.1016/j.ejca.2014.07.024. Epub 2014 Aug 26. Eur J Cancer. 2014. PMID: 25172295 Clinical Trial.
A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.
Nogami N, Takigawa N, Hotta K, Segawa Y, Kato Y, Kozuki T, Oze I, Kishino D, Aoe K, Ueoka H, Kuyama S, Harita S, Okada T, Hosokawa S, Inoue K, Gemba K, Shibayama T, Tabata M, Takemoto M, Kanazawa S, Tanimoto M, Kiura K. Nogami N, et al. Among authors: kato y. Lung Cancer. 2015 Feb;87(2):141-7. doi: 10.1016/j.lungcan.2014.11.001. Epub 2014 Nov 8. Lung Cancer. 2015. PMID: 25534129 Clinical Trial.
Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review.
Hotta K, Kato Y, Leighl N, Takigawa N, Gaafar RM, Kayatani H, Hirata T, Ohashi K, Kubo T, Tabata M, Tanimoto M, Kiura K. Hotta K, et al. Among authors: kato y. PLoS One. 2015 Mar 16;10(3):e0121211. doi: 10.1371/journal.pone.0121211. eCollection 2015. PLoS One. 2015. PMID: 25775395 Free PMC article. Review.
Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703.
Kudo K, Hotta K, Ichihara E, Yoshioka H, Kunimasa K, Tsubouchi K, Iwasaku M, Kato Y, Oze I, Takigawa N, Tanimoto M, Kiura K. Kudo K, et al. Among authors: kato y. Cancer Chemother Pharmacol. 2015 Aug;76(2):251-6. doi: 10.1007/s00280-015-2789-5. Epub 2015 Jun 3. Cancer Chemother Pharmacol. 2015. PMID: 26037206
Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience.
Oda N, Hotta K, Yoshioka H, Kudo K, Ichihara E, Kato Y, Ninomiya K, Minami D, Ninomiya T, Kubo T, Ohashi K, Sato A, Takigawa N, Tabata M, Tanimoto M, Kiura K. Oda N, et al. Among authors: kato y. Cancer Chemother Pharmacol. 2016 Nov;78(5):941-947. doi: 10.1007/s00280-016-3146-z. Epub 2016 Sep 2. Cancer Chemother Pharmacol. 2016. PMID: 27590708
8,697 results